Dr. Richard B. Marshak joined TriSalus in June 2022 and serves as Senior Vice President, Business Development & Strategy. Richard’s focus is leading the planning and execution of TriSalus’s critical business development and partnership efforts while also envisioning and guiding the SD-101 go-to-market strategy. Richard brings nearly 25 years of experience in the pharmaceutical and biotech space, spanning early discovery through commercialization. During this time, he led a broad range of strategic transactions and had major roles in more than 13 product launches while at Abbott.
Prior to joining TriSalus, Richard was Managing Principal of LF Consulting, providing strategic consulting services to a range of companies, helping to guide critical decisions around product development, corporate development, and commercialization strategies. Richard also served as an Advisor to EMA Partners, a boutique investment bank. During this period he co-founded and served as Chief Business Officer at Nephraegis Therapeutics where he remains on the board of directors. He also served as CEO of Mount Tam Biotechnologies, a biotechnology company spun out of the Buck Institute for Research on Aging, focused on developing novel mTOR modulators to improve the health and well-being of patients suffering from a range of serious diseases.
Prior to this Richard spent 15 years at Abbott/Abbvie in roles spanning marketing, business development, strategic planning, and general management in the Pharmaceutical Products Group. These included General Manager of the Pain Care Franchise and General Manager Alliance Management & Strategic Planning where responsibilities included US business development and global commercial assessment of all licensing opportunities.
Before his time in the pharmaceutical industry, Richard was an equine veterinarian in Pennsylvania. He holds VMD and BA degrees from the University of Pennsylvania and an MBA from the University of Chicago’s Booth School of Business.
